International biotech investor: Raising capital has become more difficult
But there is still money to be made for the ”good companies”, and although obesity is currently in focus, it doesn’t take the attention away from other therapeutic areas, shows Novo Holdings analysis.
Wars in Europe, inflation, high interest rates, recession, supply crunch and rising energy prices are making biotech investors around the world wary.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
